Details

Autor(en) / Beteiligte

• Youle, Mike
• Staszweski, Schlomo
• Clotet, Bonaventura
• Arribas, José Ramon
• Blaxhult, Anders
• Carosi, Giampiero
• DeJesus, Edwin
• Di Perri, Gianni
• Estrada, Vicente
• Fisher, Martin
• Kovacs, Colin
• Kulasegaram, Ranjababu
• Lazzarin, Adriano
• Marriott, Debbie
• Muñoz, Leopoldo
• Reynes, Jacques
• Shalit, Peter
• Slim, Jihad
• Tsoukas, Chris
• Vaccaro, Anthony
• Vera, José

Titel

Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations

Ist Teil von

• HIV clinical trials, 2006-03, Vol.7 (2), p.86-96

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Recent data from clinical trials investigating the efficacy of enfuvirtide, a fusion inhibitor, in treatment-experienced patients have revealed that the addition of enfuvirtide (ENF) to an active boosted protease inhibitor regimen doubles the rate of virological response. At week 48 of the TORO studies, 55% of patients previously naive to and receiving lopinavir/ritonavir (LPV/r) with ENF achieved a viral load of <400 copies/mL compared with 24% of patients treated with LPV/r alone. At week 24 of the RESIST studies, 70% of previously ENF-naive patients who took both ENF and tipranavir/ritonavir (TPV/r) achieved a ≥1 log 10 reduction in viral load compared with 37% of such patients treated with TPV/r alone. Similarly, concomitant use of TMC114/ritonavir (TMC114/r) with ENF, compared with TMC114/r alone, increased the number of patients with <50 copies/mL from 46% to 64% in a combined 24-week analysis from the POWER trials. Data from these trials suggest that combining one agent from a new class with a new agent from a previously exposed class offers a greater chance of achieving full virological control than either type of agent alone. Undetectable viraemia should be the primary objective for treatment-experienced patients requiring a switch in therapy, and the present data support the combination of an active boosted protease inhibitor with an agent from a new class (e.g., ENF) for triple-class-experienced patients.